表紙
市場調查報告書

生物相似藥的全球市場:胰島素、干擾素、Etanercept、Infliximab、Rituximab、升糖素、抑鈣素 - 至2025年的預測

Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease) - Global Forecast to 2025

出版商 MarketsandMarkets 商品編碼 930112
出版日期 內容資訊 英文 187 Pages
訂單完成後即時交付
價格
生物相似藥的全球市場:胰島素、干擾素、Etanercept、Infliximab、Rituximab、升糖素、抑鈣素 - 至2025年的預測 Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract), Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease) - Global Forecast to 2025
出版日期: 2020年03月24日內容資訊: 英文 187 Pages
簡介

全球生物相似藥市場規模預測將從2020年的118億美元,到2025年達到357億美元,在預測期間內預計將以年複合成長率24.7%的速度成長。促進該市場成長的主要原因,是由於慢性疾病的發生率增加及成本效益高的生物相似藥的需求增加。各產品中的單株抗體市場區隔,在預測期間內預計將以最高年複合成長率成長。該市場區隔的成長,主要起因於新產品的銷售/批准數量的增加,癌症疾病的發生率增加。

本報告提供全球生物相似藥市場相關調查分析,各市場區隔、各地區的市場分析與預測,市場發展的影響要素,競爭環境,及主要企業等相關的系統性資訊。

第1章 簡介

第2章 調查手法

第3章 摘要整理

第4章 重要考察

  • 生物相似藥市場概要
  • 北美的生物相似藥市場:各產品
  • 生物相似藥市場地區概要

第5章 法規預測

  • 北美
    • 美國
    • 加拿大
  • 歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
  • 其他地區
    • 巴西
    • 墨西哥
    • 阿根廷
    • 沙烏地阿拉伯

第6章 市場概要

  • 簡介
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
    • 趨勢

第7章 生物相似性藥市場:各產品

  • 簡介
  • 單株抗體
    • Infliximab
    • Rituximab
    • TRASTUZUMAB
    • Adalimumab
    • 其他的單株抗體
  • 胰島素
  • 顆粒細胞增生因子
  • 促血紅細胞生長素
  • 基因重組人體生長荷爾蒙
  • Etanercept
  • 促濾泡素
  • 特立帕肽
  • 干擾素
  • Enoxaparin Sodium
  • 升糖素
  • 抑鈣素

第8章 生物相似藥市場:生產各類型

  • 簡介
  • 自家公司生產
  • 契約生產

第9章 生物相似藥市場:各適應症

  • 簡介
  • 癌症
  • 慢性疾病
  • 自體免疫疾病
  • 血液疾病
  • 生長激素缺乏症
  • 感染疾病
  • 其他

第10章 生物相似藥市場:各地區

  • 簡介
  • 歐洲
  • 亞太地區
  • 北美
  • 南美
  • 中東、非洲

第11章 競爭情形

  • 概要
  • 市場佔有率分析
  • 競爭模式
  • 競爭領導製圖

第12章 企業簡介

  • SANDOZ
  • PFIZER
  • ELI LILLY
  • TEVA PHARMACEUTICAL
  • CELLTRION
  • BIOCON
  • AMGEN
  • SAMSUNG BIOLOGICS
  • MYLAN
  • DR. REDDY'S LABORATORIES
  • STADA ARZNEIMITTEL AG
  • COHERUS BIOSCIENCES
  • BIOCAD
  • AMEGA BIOTECH
  • PROBIOMED
  • BOEHRINGER INGELHEIM
  • APOTEX
  • FRESENIUS KABI
  • GEDEON RICHTER
  • MABXIENCE

第13章 附錄

目錄
Product Code: BT 2160

"The global biosimilars market size is projected to register a CAGR of 24.7% during the forecast period."

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%. Growth in this industry is driven by the rising incidence of chronic diseases and the increasing demand for biosimilars due to their cost-effectiveness. On the other hand, complexities in manufacturing restraining the market.

"The monoclonal antibody segment is anticipated to grow at the fastest growth rate during the forecast period."

The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is driven mainly by the increasing number of product launches/approvals, rising incidences of cancer diseases.

"The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period."

Based on the treatment site, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to remain the fastest-growing segment of the global market during the biosimilars period. Its benefits, particularly for small players in the market or those that do not have sufficient infrastructure and resources for efficient manufacturing, are driving growth.

"Asia Pacific is estimated to register the highest CAGR during the study period."

Geographically, the biosimilars market is dominated by Europe and followed by Asia Pacific in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. The rising aging population, coupled with the massive demand for cost-effective alternative pharmaceuticals, will drive the market in the region over the forecast period.

Breakdown of Profiles of Primary Participants:

  • By Company Type: Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
  • By Designation: C-level: 30%, Director-level: 34%, and Others: 36%
  • By Region: North America: 40%, Europe: 28%, Asia Pacific: 20%, and the Rest of the World: 12%

The key players in the biosimilars market include: Pfizer (US), Sandoz (Germany), Biocon (India), Biogen (US), Fresenius Kabi AG (Germany), Boehringer Ingelheim (Germany), Merck KgaA, Mylan (US), Eli Lilly (US), Teva Pharmaceutical (Israel), Dr. Reddy's Laboratories (India), Amgen (US), Celltrion (South Korea), Samsung Biologics (South Korea), Amega Biotech (Argentina), mAbxience (Switzerland), Probiomed (Mexico), Apotex (Canada), Chong Kun Dang (South Korea), JCR Pharmaceuticals (Japan), Gan & Lee Pharmaceuticals (China), Gedeon Richter (Hungary), Biocad (Russia), Coherus Bioscience (US), and Stada Arzneimittel AG (Germany).

Research Coverage:

The report analyzes the biosimilars market by product, type of manufacturing, indication, and region. Apart from comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by market players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms and new entrants/smaller firms to gauge the pulse of the market, which, in turn, will help these firms garner greater market shares. Firms purchasing the report can use any one, or a combination of the below mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the services of the top players in the biosimilars market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
  • Market Development: Detailed information about emerging markets.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 MARKET SCOPE
  • 1.4 YEARS CONSIDERED FOR THE STUDY
  • 1.5 CURRENCY
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 SECONDARY DATA
    • 2.2.1 SECONDARY SOURCES
  • 2.3 PRIMARY DATA
    • 2.3.1 KEY DATA FROM PRIMARY SOURCES
  • 2.4 MARKET SIZE ESTIMATION
    • 2.4.1 BOTTOM-UP APPROACH
    • 2.4.2 GROWTH FORECAST
    • 2.4.3 TOP-DOWN APPROACH
  • 2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.6 ASSUMPTIONS FOR THE STUDY
  • 2.7 LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 BIOSIMILARS MARKET OVERVIEW
  • 4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2019
  • 4.3 GEOGRAPHICAL SNAPSHOT OF THE BIOSIMILARS MARKET

5 REGULATORY OUTLOOK

  • 5.1 NORTH AMERICA
    • 5.1.1 US
    • 5.1.2 CANADA
  • 5.2 EUROPE
  • 5.3 ASIA PACIFIC
    • 5.3.1 CHINA
    • 5.3.2 INDIA
    • 5.3.3 JAPAN
    • 5.3.4 SOUTH KOREA
    • 5.3.5 AUSTRALIA
  • 5.4 REST OF THE WORLD
    • 5.4.1 BRAZIL
    • 5.4.2 MEXICO
    • 5.4.3 ARGENTINA
    • 5.4.4 SAUDI ARABIA

6 MARKET OVERVIEW

  • 6.1 INTRODUCTION
  • 6.2 MARKET DYNAMICS
    • 6.2.1 DRIVERS
      • 6.2.1.1 Increasing demand for biosimilar drugs
      • 6.2.1.2 Rising incidence of chronic diseases
    • 6.2.2 RESTRAINTS
      • 6.2.2.1 Complexities in manufacturing
      • 6.2.2.2 Resistance from biologic manufacturers
    • 6.2.3 OPPORTUNITIES
      • 6.2.3.1 Emerging markets
      • 6.2.3.2 New indications and the patent expiry of biologic products
    • 6.2.4 CHALLENGES
      • 6.2.4.1 Stringent regulatory requirements
    • 6.2.5 TRENDS
      • 6.2.5.1 Collaborations for biosimilar research and clinical trials

7 BIOSIMILARS MARKET, BY PRODUCT

  • 7.1 INTRODUCTION
  • 7.2 MONOCLONAL ANTIBODIES
    • 7.2.1 INFLIXIMAB
      • 7.2.1.1 Infliximab accounted for the largest share of the monoclonal antibodies market
    • 7.2.2 RITUXIMAB
      • 7.2.2.1 Rising incidence of autoimmune diseases and cancer are key drivers of market growth
    • 7.2.3 TRASTUZUMAB
      • 7.2.3.1 Rising incidences of cancer will drive market growth
    • 7.2.4 ADALIMUMAB
      • 7.2.4.1 Adalimumab will register the highest CAGR in the monoclonal antibodies market
    • 7.2.5 OTHER MONOCLONAL ANTIBODIES
  • 7.3 INSULIN
    • 7.3.1 INCREASING INCIDENCE OF DIABETES WILL SUPPORT MARKET GROWTH
  • 7.4 GRANULOCYTE COLONY-STIMULATING FACTOR
  • 7.5 ERYTHROPOIETIN
    • 7.5.1 RISING INCIDENCE OF BLOOD DISORDERS WILL DRIVE MARKET GROWTH
  • 7.6 RECOMBINANT HUMAN GROWTH HORMONE
    • 7.6.1 MARKET GROWTH IS DRIVEN PRIMARILY BY THE INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS
  • 7.7 ETANERCEPT
    • 7.7.1 APAC MARKET FOR ETANERCEPT WILL SHOW THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • 7.8 FOLLITROPIN
    • 7.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT WILL DRIVE MARKET GROWTH
  • 7.9 TERIPARATIDE
    • 7.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS IS THE MAIN GROWTH DRIVER FOR THIS MARKET
  • 7.10 INTERFERONS
    • 7.10.1 MARKET GROWTH IS SUPPORTED BY THE RISING INCIDENCE OF INFECTIOUS DISEASES
  • 7.11 ENOXAPARIN SODIUM
    • 7.11.1 WIDE RANGE OF APPLICATIONS HAVE SUPPORTED THE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
  • 7.12 GLUCAGON
    • 7.12.1 SANDOZ IS A MAJOR PLAYER IN THE GLUCAGON BIOSIMILARS MARKET
  • 7.13 CALCITONIN
    • 7.13.1 INCREASING INCIDENCE OF OSTEOPOROSIS WILL DRIVE THE MARKET

8 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING

  • 8.1 INTRODUCTION
  • 8.2 IN-HOUSE MANUFACTURING
    • 8.2.1 COST-EFFECTIVENESS MAKES IN-HOUSE MANUFACTURING HIGHLY PREFERABLE FOR MOST MARKET PLAYERS
  • 8.3 CONTRACT MANUFACTURING
    • 8.3.1 OUTSOURCING PRODUCTION ENABLES COMPANIES TO FOCUS ON CORE COMPETENCY AND PROVIDES COST-BENEFITS

9 BIOSIMILARS MARKET, BY INDICATION

  • 9.1 INTRODUCTION
  • 9.2 ONCOLOGY
    • 9.2.1 RISING BURDEN OF CANCER AND GROWING INCIDENCE HAVE DRIVEN DEMAND FOR BIOSIMILARS
  • 9.3 CHRONIC DISEASES
    • 9.3.1 HIGH EFFICACY OF BIOSIMILARS HAS DRIVEN RESEARCH INTO APPLICATIONS IN CHRONIC DISEASE TREATMENT
  • 9.4 AUTOIMMUNE DISEASES
    • 9.4.1 GROWING RESEARCH ACTIVITY FOR AUTOIMMUNE DISEASE INDICATIONS WILL FAVOR MARKET GROWTH
  • 9.5 BLOOD DISORDERS
    • 9.5.1 POSSIBILITY OF COST-REDUCTIONS IN BLOOD DISORDER TREATMENT WILL SUPPORT MARKET DEMAND FOR BIOSIMILARS
  • 9.6 GROWTH HORMONE DEFICIENCY
    • 9.6.1 GROWING CASES OF GH DEFICIENCY DRIVES DEMAND FOR BIOSIMILARS
  • 9.7 INFECTIOUS DISEASES
    • 9.7.1 ASIA PACIFIC SHOWS HIGHEST DEMAND FOR BIOSIMILARS IN THIS SEGMENT
  • 9.8 OTHER INDICATIONS

10 BIOSIMILARS MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 EUROPE
    • 10.2.1 UK
      • 10.2.1.1 The UK holds the largest share of the biosimilars market in Europe
    • 10.2.2 FRANCE
      • 10.2.2.1 Rising geriatric population will drive market growth
    • 10.2.3 GERMANY
      • 10.2.3.1 The presence of a favorable pricing system has supported biosimilar adoption in Germany
    • 10.2.4 ITALY
      • 10.2.4.1 Rising geriatric population in Italy will support market growth
    • 10.2.5 SPAIN
      • 10.2.5.1 R&D investments for the development of innovative drugs is a key growth driver in the Spanish market
    • 10.2.6 REST OF EUROPE
  • 10.3 ASIA PACIFIC
    • 10.3.1 INDIA
      • 10.3.1.1 India holds the largest share of the APAC market
    • 10.3.2 CHINA
      • 10.3.2.1 China accounts for the second-largest share of the APAC market
    • 10.3.3 SOUTH KOREA
      • 10.3.3.1 Rising incidences of chronic diseases are expected to drive the market in South Korea
    • 10.3.4 JAPAN
      • 10.3.4.1 Growing geriatric population is expected to drive the market in Japan
    • 10.3.5 AUSTRALIA
      • 10.3.5.1 Increasing number of product launches will drive market growth
    • 10.3.6 REST OF ASIA PACIFIC
  • 10.4 NORTH AMERICA
    • 10.4.1 US
      • 10.4.1.1 US will dominate the North American biosimilars market
    • 10.4.2 CANADA
      • 10.4.2.1 Increasing incidences of chronic diseases will drive market growth in Canada
  • 10.5 LATIN AMERICA
    • 10.5.1 RISING INCIDENCES OF CANCER WILL DRIVE MARKET GROWTH
  • 10.6 MIDDLE EAST AND AFRICA
    • 10.6.1 FAVORABLE HEALTHCARE REFORMS AND INFRASTRUCTURAL DEVELOPMENT WILL FAVOR MARKET GROWTH

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET SHARE ANALYSIS, 2018
  • 11.3 COMPETITIVE SCENARIO
    • 11.3.1 PRODUCT LAUNCHES AND APPROVALS
    • 11.3.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
    • 11.3.3 ACQUISITIONS
    • 11.3.4 EXPANSIONS
  • 11.4 COMPETITIVE LEADERSHIP MAPPING (2018)
    • 11.4.1 VENDOR INCLUSION CRITERIA
    • 11.4.2 VISIONARY LEADERS
    • 11.4.3 INNOVATORS
    • 11.4.4 DYNAMIC DIFFERENTIATORS
    • 11.4.5 EMERGING COMPANIES

12 COMPANY PROFILES

(Business overview, Products offered, Recent developments, Product pipeline & MnM View)*

  • 12.1 SANDOZ
  • 12.2 PFIZER
  • 12.3 ELI LILLY
  • 12.4 TEVA PHARMACEUTICAL
  • 12.5 CELLTRION
  • 12.6 BIOCON
  • 12.7 AMGEN
  • 12.8 SAMSUNG BIOLOGICS
  • 12.9 MYLAN
  • 12.10 DR. REDDY'S LABORATORIES
  • 12.11 STADA ARZNEIMITTEL AG
  • 12.12 COHERUS BIOSCIENCES
  • 12.13 BIOCAD
  • 12.14 AMEGA BIOTECH
  • 12.15 PROBIOMED
  • 12.16 BOEHRINGER INGELHEIM
  • 12.17 APOTEX
  • 12.18 FRESENIUS KABI
  • 12.19 GEDEON RICHTER
  • 12.20 MABXIENCE

Details on Business overview, Products offered, Recent developments, Product pipeline & MnM View might not be captured in case of unlisted companies

13 APPENDIX

  • 13.1 INSIGHTS OF INDUSTRY EXPERTS
  • 13.2 DISCUSSION GUIDE
  • 13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4 AVAILABLE CUSTOMIZATIONS
  • 13.5 RELATED REPORTS
  • 13.6 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
  • TABLE 2: SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
  • TABLE 3: STATUS OF REGULATORY PATHWAY IN THE ASIA PACIFIC
  • TABLE 4: STATUS OF REGULATORY PATHWAY IN ROW COUNTRIES
  • TABLE 5: LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
  • TABLE 6: MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2017-2020)
  • TABLE 7: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 8: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 9: US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (UNITS)
  • TABLE 10: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 11: BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 12: BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 13: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 14: BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 15: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 16: BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 17: LIST OF APPROVED BIOSIMILARS FOR G-CSF
  • TABLE 18: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 19: LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
  • TABLE 20: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 21: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 22: BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 23: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 24: BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 25: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 26: BIOSIMILARS MARKET FOR ENOXAPARIN SODIUM, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 27: BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 28: BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 29: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 30: BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2018-2025 (USD MILLION) 66  
  • TABLE 32: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 33: BIOSIMILARS APPROVED BY THE US FDA FOR ONCOLOGICAL INDICATIONS, 2017-2019
  • TABLE 34: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 35: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 36: BIOSIMILARS APPROVED BY THE US FDA FOR CHRONIC DISEASES, 2017-2019
  • TABLE 37: BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 38: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 39: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 40: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 41: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 42: BIOSIMILARS MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 43: LIST OF BIOSIMILARS APPROVED IN EUROPE
  • TABLE 44: EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 45: EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 46: EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 47: EUROPE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 48: EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 49: LIST OF BIOSIMILARS IN THE UK
  • TABLE 50: UK: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 51: UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 52: UK: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 53: UK: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 54: FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 55: FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 56: FRANCE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 57: FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 58: LIST OF BIOSIMILARS APPROVED IN GERMANY
  • TABLE 59: GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 60: GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 61: GERMANY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 62: GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION) 92  
  • TABLE 63: ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 64: ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 65: ITALY: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 66: ITALY: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 67: SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 68: SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 69: SPAIN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 70: SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 71: ROE: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 72: ROE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 73: ROE: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 74: ROE: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 75: ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 76: ASIA PACIFIC: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 77: ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 78: ASIA PACIFIC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 79: ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 80: BIOSIMILARS APPROVED AND MARKETED IN INDIA
  • TABLE 81: INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 82: INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 83: INDIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 84: INDIA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 85: BIOSIMILARS APPROVED IN CHINA
  • TABLE 86: CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 87: CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 88: CHINA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 89: CHINA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 90: LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
  • TABLE 91: SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 92: SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 93: SOUTH KOREA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 94: SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION) 112  
  • TABLE 95: LIST OF BIOSIMILARS APPROVED IN JAPAN
  • TABLE 96: JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 97: JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 98: JAPAN: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 99: JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 100: LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
  • TABLE 101: AUSTRALIA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 102: AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 103: AUSTRALIA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 104: AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 105: LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
  • TABLE 106: LIST OF BIOSIMILARS APPROVED IN MALAYSIA
  • TABLE 107: LIST OF BIOSIMILARS APPROVED IN SINGAPORE
  • TABLE 108: ROAPAC: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 109: ROAPAC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 110: ROAPAC: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 111: ROAPAC: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 112: NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 113: NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 114: NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 115: NORTH AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 116: NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 117: LIST OF BIOSIMILARS APPROVED IN THE US
  • TABLE 118: US: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 119: US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 120: US: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 121: US: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 122: LIST OF BIOSIMILARS APPROVED IN CANADA
  • TABLE 123: CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 124: CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 125: CANADA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION) 131  
  • TABLE 126: CANADA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 127: LIST OF BIOSIMILARS APPROVED IN LATIN AMERICA
  • TABLE 128: LATIN AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 129: LATIN AMERICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 130: LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)
  • TABLE 131: MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2018-2025 (USD MILLION)
  • TABLE 132: MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2018-2025 (USD MILLION)
  • TABLE 133: MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2018-2025 (USD MILLION)

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: BIOSIMILARS MARKET, BY PRODUCT, 2020 VS. 2025 (USD BILLION)
  • FIGURE 7: BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING, 2020 VS. 2025 (USD BILLION)
  • FIGURE 8: BIOSIMILARS MARKET, BY INDICATION, 2020 VS. 2025 (USD MILLION)
  • FIGURE 9: BIOSIMILARS MARKET, BY REGION, 2020 VS. 2025 (USD BILLION)
  • FIGURE 10: RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET
  • FIGURE 11: INSULIN HELD LARGEST MARKET SHARE IN 2019
  • FIGURE 12: CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD
  • FIGURE 13: BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 14: INCREASING GERIATRIC POPULATION, BY REGION, 2019 VS. 2050
  • FIGURE 15: GLOBAL INCIDENCE OF DIABETES, BY REGION, 2019, 2030, 2045
  • FIGURE 16: ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET
  • FIGURE 17: ARTICLES PUBLISHED ON BIOSIMILARS FOR ONCOLOGY, 2010-2018
  • FIGURE 18: ARTICLES PUBLISHED ON BIOSIMILARS FOR CHRONIC DISEASES, 2010-2018
  • FIGURE 19: ARTICLES PUBLISHED ON BIOSIMILARS FOR AUTOIMMUNE DISEASES, 2010-2018
  • FIGURE 20: ARTICLES PUBLISHED ON BIOSIMILARS FOR BLOOD DISORDERS, 2010-2018
  • FIGURE 21: ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD
  • FIGURE 22: EUROPE: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 23: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE UK, 2010-2018
  • FIGURE 24: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN FRANCE, 2010-2018
  • FIGURE 25: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN GERMANY, 2010-2018
  • FIGURE 26: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN ITALY, 2011-2019
  • FIGURE 27: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN SPAIN, 2010-2018
  • FIGURE 28: ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 29: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN THE US, 2010-2018
  • FIGURE 30: PROJECTED INCREASE IN CANCER INCIDENCE IN CANADA
  • FIGURE 31: ARTICLES ON BIOSIMILAR RESEARCH PUBLISHED IN CANADA, 2010-2018
  • FIGURE 32: KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2017 TO 2020
  • FIGURE 33: GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
  • FIGURE 34: MNM DIVE-VENDOR COMPARISON MATRIX: BIOSIMILARS MARKET
  • FIGURE 35: SANDOZ: COMPANY SNAPSHOT
  • FIGURE 36: PFIZER: COMPANY SNAPSHOT 146  
  • FIGURE 37: ELI LILLY: COMPANY SNAPSHOT
  • FIGURE 38: TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
  • FIGURE 39: CELLTRION: COMPANY SNAPSHOT
  • FIGURE 40: BIOCON: COMPANY SNAPSHOT
  • FIGURE 41: AMGEN: COMPANY SNAPSHOT
  • FIGURE 42: SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
  • FIGURE 43: MYLAN: COMPANY SNAPSHOT
  • FIGURE 44: DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 45: STADA ARZNEIMITTEL: COMPANY SNAPSHOT
  • FIGURE 46: BOEHRINGER INGELHEIM: COMPANY SNAPSHOT